IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN

Early highly active antiretroviral therapy is recommended in all vertically human immunodeficiency virus (HIV)-infected infants. We describe the long-term immunologic outcome after planned treatment interruption (PTI) in 7 children diagnosed and treated during acute HIV infection (age < 12 weeks)...

Descripción completa

Detalles Bibliográficos
Autores: Fortuny C, Noguera-Julian A, Alsina L, Bellido R, Sánchez E, Muñoz-Almagro C, Ruiz L, Jiménez R
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2011
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p1038
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1038
Access Level:acceso abierto
Palabra clave:acute HIV infection
vertically transmitted HIV infection
highly active antiretroviral therapy
immunologic evolution
treatment interruption
Descripción
Sumario:Early highly active antiretroviral therapy is recommended in all vertically human immunodeficiency virus (HIV)-infected infants. We describe the long-term immunologic outcome after planned treatment interruption (PTI) in 7 children diagnosed and treated during acute HIV infection (age < 12 weeks). Children had remained a median of 57 months off treatment, 3 of them indefinitely. The 2 patients with the lowest nadir CD4% reinitiated highly active antiretroviral therapy because of a CD4 cell decline of < 20%; 2 children resumed treatment because of clinical progression and parents' wishes. All patients experienced a decrease in CD4% after PTI, which particularly affected the naive subpopulation. The interferon-gamma response against HIV-p24 antigen directly correlated with nadir CD4%. Our results suggest that early treatment in HIV-infected infants increases their potential to safely control viral replication after PTI for long periods.

Similares en LA Referencia